* If you want to update the article please login/register
Evaluate the relationship between oral simvastatin's use in short-term revision of Ki-67 as a candidate biomarker of breast tumor formation among women with clinical stage 1 or 2-primary invasive breast cancer. In groups classified by tumor expression of hydroxymethylglutaryl co-enzyme A reductase, estrogen receptor /progesterone receptor status, HER2neu, and tumor grade, to perform exploratory studies comparing the effect of statins on breast tumor formation and apoptosis in breast tumor proliferation and apoptosis. OUTLINE: Patients are treated with simvastatin orally daily for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
Source link: https://clinicaltrials.gov/ct2/show/NCT03454529
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions